BioCentury
@BioCentury
Followers
16K
Following
4K
Media
884
Statuses
39K
The leading voice for decision-makers throughout the global biopharma ecosystem. Follow us on LinkedIn for exclusive insights & analysis: https://t.co/V33Z1gfUfZ
Joined December 2010
How NCI's cancer-focused national lab is stepping up to validate #COVID19 serological tests, uncover genetics of severe disease and find covalent inhibitors of viral proteins
1
19
41
Fred Frank, co-founder of the biotech industry, is dead at 89.
1
6
33
With ALS action plan, @US_FDA aims for patient engagement, but #ALS advocates such as @iamalsorg's @bsw5020 say the blueprint lacks urgency, noting that the agency’s timeline exceeds the life expectancy of most current patients
3
15
31
#ALS community ends year with a win at the White House as #ACTforALS becomes law, earmarking $100M annually to increase access to therapies
3
20
32
Rising serial entrepreneur Akiko Iwasaki has shown that increasing lymphatic drainage in the brain can prime immune responses to clear brain tumors. The work could lead to third cancer start-up out of @VirusesImmunity's lab this year.
0
6
26
Roche is looking to make CNS a growth driver to match oncology this next decade. Partnering with small and large companies will be a big part of that.
1
11
29
ICYMI: Formed by @kiranshaw, Kush Parmar and @DrSidMukherjee, Bangalore's Immuneel plans to bring a #CART therapy to cancer patients in India for about $50K per treatment
4
11
27
ICYMI: The last two decades of drug approvals suggest the #RuleofFive is losing its grip on medicinal chemistry. Is it time to abandon the concept of "drug-like properties"? @Novartis @abbvie.
3
20
23
Into #NKcells before they were cool: @affimed's long journey to find the right settings and combinations for its innate cell engager bispecifics is finally getting investors' attention; story from @StephenPHansen in @BioCentury
0
6
25
Immuneel, India cancer cell therapy co from @kiranshaw, Kush Parmar and @DrSidMukherjee, in-licenses its first CAR T therapy.
0
7
24
Targeted degradation steps out of cellular bounds with new platforms from the labs of @ArvinasInc founder @CraigMCrews and @Palleon_Pharma founder @CarolynBertozzi
0
7
22
Why @scrippsresearch consolidated three institutes, created a non-profit portfolio fund and doubled down on phenomics-based target discovery.
0
10
22
Bob Nelsen, co-founder of Arch Ventures Partners, on AI creating a "language of biology," responding to the China challenge, and focusing on big opportunities.
0
4
22
Luciana Borio (@llborio) joins Arch as venture partner, brings expertise, FDA, White House experience in biodefense and public health and will focus on manufacturing, clinical trials, novel therapies. Firm promotes Carol Suh to partner
2
3
18
FDA Commissioner @SGottliebFDA wants bang for regulatory buck, via interview with BioCentury's @steveusdin1.
0
14
16
How @Immunocore’s $100M deal with @Genentech gives the #TCR bispecific play enough runway to justify its lofty valuation. @StephenPHansen explores in this week’s BioCentury
0
9
19
There are now eight #COVID19 vaccines in the clinic: a graphical comparison of the current clinical vaccine modalities.
0
9
17
Kymera's latest Ph I data shows its IRAK4 protein degrader KT-474 reaches 96% degradation and inhibits induction of eight pro-inflammatory cytokines $KYMR
0
4
17
ICYMI: In a Guest Commentary, @ScottGottliebMD says @US_FDA is “on the cusp of a major cultural shift” that will transform the way the agency reviews drugs.
1
10
18
. @atlasventure's Bruce Booth sees biotech's belt-tightening starting to yield more favorable financing environment, but there's still pain to come. how new modalities will play out. Watch @LifeSciVC in conversation @BioCentury's @FishburnSimone
0
3
17
Over 200 COVID-19 trials could read out this summer; BioCentury breaks them down by therapeutic mechanism, size, phase and comparator.
0
15
18
Merck acquires Calporta for up to $576 million, one of eight companies from the $GSK-Avalon Ventures' 2013 build-to-buy deal. Calporta is developing #TRPML1 agonists for lysosomal storage and neurodegenerative disorders like #alzheimers and #parkinsons
0
8
18
Data Byte: Phase I data suggest Inovio's #COVID19 vax is more effective at stimulating T cells than neutralizing antibody responses $INO
2
6
16
Exclusive fireside chat with @FishburnSimone reveals how @Roche pharma’s years-long pursuit of @ArrakisTx finally yielded one of the largest early-stage deals it has ever entered @michael_gilman #COVID19 .Listen now:
0
3
17
Biocon’s path to affordable innovation: A conversation with Kiran Mazumdar Shaw on #TheBioCenturyShow. @kiranshaw @BioconBiologics
2
8
17
10 PDUFA dates on deck in November: a BioCentury data byte $ETON $LQDA $BMRN $AADI $FENC $LEGN $JNJ $AMYT $BYSI $CTIC $VBIV
0
4
15
Hereditary angioedema proves to be an ideal proof-of-concept indication for in vivo gene editing from @intelliatx with new NTLA-2001 supporting a clear dose response in gene expression and near flawless clinical efficacy in first 10 patients
0
2
14
BMS is paying Agenus $200M up front for global rights to a bispecific antibody targeting TIGIT $AGEN
1
7
15
Ocrevus, an injectable, has overturned the "small molecule is better" paradigm in MS. What does that mean for the next drugs coming to market? $NVS $CELG
1
5
16
ICYMI: BioCentury Innovations' @Laurenmmartz explores why new targets at #AACR18 suggest non-coding RNAs are on the rise
0
5
16
@NPLB_org proposes updated cost-effectiveness methodology that accounts for disease severity, loss of market exclusivity and social value
0
9
15
Check out the #JPM2021 Guide that @macbiocom and BioCentury have teamed up to create . #JPM21 #Biotechshowcase #healthcarepartneringweek @pharmaceutical
0
4
16
BIO launches a #COVID19 vaccine facts website to provide vaccine education through trusted messengers. @IamBiotech
0
8
15
How new @Medicxi company Divide & Conquer, co-founded by @sciencescanner, aims to capitalize on new biology that could prevent cancer cells from sharing resistance mechanisms via multicellular networks
0
10
14
From dinner in Basel to Zoom under lockdown: James Sabry and @michael_gilman talk to Editor in Chief @FishburnSimone about how the Roche-Arrakis deal came about. @ArrakisTx @Roche
0
6
14
GI Band-Aid: How preventing bacteria from escaping the gut could treat autoimmunity
1
12
13
Antibody-drug conjugates outnumber traditional antibodies in BioCentury's translational trend analysis based on first-in-human abstracts at #AACR23
0
2
14
#ALS patients are demanding greater regulatory flexibility from FDA that would enable broader access to therapies in the clinic. Doing so could generate a wealth of data @iamalsorg @alsassociation
5
8
15
In this week's @BioCentury, @StephenPHansen looks at why @medicxi committed up to EUR 40M to spin out two orexin agonist programs from @soseiheptaresco
0
4
14
Anti-China bills portend massive blow to biotech. According to a BioCentury survey, an overwhelming majority of biotechs expect pipeline setbacks; many oppose BIO’s reversal
0
8
13
Gilead's antiviral remdesivir almost completely resolved the symptoms of a U.S. patient infected with the coronavirus; now the biotech is planning a Chinese trial $GILD #2019nCov
1
4
14
BioCentury's #ASCO18 abstract roundup suggests that away from the PD-1 herd, researchers are trying many new strategies, modalities and targets to solve big problems in cancer
0
13
14
5AM Ventures closes 5AM Opportunities I fund and 5AM Ventures VI fund, raising total of $497 million.
1
6
13
#2019nCoV diagnostics, critical for patient care and public health, are starting to be deployed widely
0
3
7
Remembering Fred Frank, a giant of biotech: @jmaxlevin, @ps_onlyconnect pay tribute to Frank, investment banker and early architect of the biotech industry
0
6
13
ICYMI: @MIT Professor Christopher Love's latest foray into benchtop manufacturing of biologics has yielded the InSCyT system, which produces clinical-quality proteins in just three days, suggesting it is nearly ready for industry use.
0
4
11
Lining up efficacy and immunogenicity data from the first #COVID19 vaccines reveals the first hints of correlates of protection
0
13
13
Biogen's SMA therapy Spinraza yields long-term preservation of motor development and function on par with Zolgensma gene therapy data. $BIIB
0
5
13
Drive-by analysis of accelerated approval is intellectual malpractice. Medical journals and news publications have incorrectly concluded that half of cancer accelerated approvals are useless. BioCentury's @steveusdin1 explains why.
1
9
13
How Nektar’s PEGs turned IL-2 into a viable immunotherapy partner for BMS
0
7
13
Congrats to the 2019 BayHelix China Healthcare Award winners, announced last week during the 6th BioCentury-BayHelix China Healthcare Summit in Shanghai. $BGNE $AMGN $FGEN $ZLAB.
0
2
11
The latest revival of 38-yr-old $CLDX comes on the back of urticaria program CDX-0159, with Ph Ib data presented at #EAACI2021 showing 95% complete response rate. @StephenPHansen speaks with #Celldex CEO Anthony Marucci and CSO Tibor Keler
0
4
12
.@biogen may have called off trials of aducanumab, but the amyloid hypothesis of Alzheimer's disease lives on. @BioCentury's @SelinaMKoch asks companies what data could make them walk away.
1
4
12
ICYMI: Solid hopes: Next-gen T cell bispecifics hope solid tumor success can differentiate them from CAR Ts and checkpoint inhibitors
0
4
12
The Quiet Disrupters: How a technology to encode mAbs in RNA or DNA is quietly growing, with the potential to upend the standard way biologics are manufactured.
1
7
10
.@ScottGottliebMD sits down with @steveusdin1 to discuss pandemic preparedness, regulatory innovation and FDA’s future during #BioCenturyShow tomorrow >> Register for open access: . @US_FDA @pharmaceutical #pandemic #biotech #lifesciences #FDA
0
8
11
.@PureTechH subsidiary Vor's engineered HSCs platform could eliminate on-target toxicity for CAR Ts and open up new targets for non-B cell cancers
0
8
12
FDA Commissioner @DrCaliff_FDA calls misinformation "leading cause of death," vows plan to combat it.
3
4
11
A trial funded by @CureDuchenne, @MDAorg and @ParentProjectMD aims to solve the AAV redosing problem. If successful, it could have major impact on patient care and gene therapy pipeline strategies.
0
5
12
.@ARPA_H backs @EveryCure's drug- and disease-agnostic approach to drug repurposing with $48.3M #rarediseaseday2024 #raredisease
0
3
11
#FTC report highlights role of small companies in developing drugs, makes case that large companies acquiring small companies supports innovation.
0
6
12
With @US_FDA's approval of tofersen from @Biogen, @ionispharma, neurofilament becomes ‘anchor’ biomarker in #ALS
0
6
11
.@JMaraganore talks to @FishburnSimone on The BioCentury Show about the convergence of an innovation explosion and a rising bar for investment, and why that's good for biotech. Plus, views on the Inflation Reduction Act, Biosecure Act, and more.
0
4
10
Gap in early stage funding for antibiotics companies leads @NovoHoldings to launch $165M REPAIR Impact Fund to invest in antimicrobial resistance plays
0
5
11
BioCentury launches free #COVID19 Resource Center for the biomedical community to aid in the development of #coronavirus countermeasures and to help companies navigate the business impacts during the crisis.
0
11
10
How OSI has leveraged a foundational deal with @UniofOxford into an $800M+ evergreen fund and an expanding life sciences portfolio. BioCentury's @StephenPHansen speaks with OSI's Lachlan MacKinnon & @UcianeScarlett. @OSI_Updates
0
3
10
In a first, FDA recognizes genetic database, removing regulatory hurdle
0
3
10
Trading of Everest's shares is to begin Friday in Hong Kong after the mainland China company priced what could become the biggest IPO yet since @HKEXGroup opened its biotech chapter in 2018
0
7
10
Formed by @kiranshaw, Kush Parmar and @DrSidMukherjee, Bangalore's Immuneel plans to bring a #CART therapy to cancer patients in India for about $50K per treatment
1
4
11
New CAR designs at #ASH18: BioCentury's infographic highlights CARs designed for multi-antigen targeting, overcoming PD1 and boosting tumor homing, and shows where to find them.
2
3
10
How data from past trials, RWD and simulations are are being deployed to build external control arms for clinical trials
0
7
9
How lymphatics discoveries could yield new opportunities for PureTech
0
5
10
As @CEPIvaccines looks to prepare for the next pandemic, it has set a lofty goal to reduce to 100 days the time from sequencing the pathogen to a regulatory submission of a vaccine. But, what will it take?
0
3
10
BioCentury maps readouts from COVID-19 clinical trials to disease stage and therapeutic mechanism.
0
7
8
Codiak and Sarepta team up to develop AAV-stuffed exosomes for repeat dosing of nucleic acid therapies. $SRPT
0
2
10
How drug developers are thinking about the recent report of the surprising marriage of carbohydrates and RNA.
0
4
9
How academics are helping companies harness the microbiome for immuno-oncology
0
2
10
BioCentury proudly supports @kendallsqorch and their #Symphony for Science 2022 in #Boston benefiting @SCFG! . Tickets are on sale now at
0
4
10
Can CAR T cells move beyond cancer? The answer might depend on whether allogeneic technologies take off
0
5
10
POC for cytokines: Cytokines are emerging as a logical combination partner to boost PD-1 responses
0
4
10
.@healx has an AI-based platform to repurpose drugs for rare disease and is building the patient voice into its discovery process. The $56M series B round the U.K. company raised Wednesday will help bring its #FragileXSyndrome into the clinic
0
4
9
EXCLUSIVE: Gottlieb’s Exit Interview. Just days after his resignation, @ScottGottliebMD talks with BioCentury’s @steveusdin1 about what he's done, what he thinks was most important, and what will carry forward. (Read with subscription or trial sub.)
0
13
8
ICYMI: For first-time academic entrepreneurs, the challenge is establishing industry bona fides
0
3
10
FDA approves Foundation Medicine's cancer Dx, CMS proposes coverage
1
3
9
Aspect raises $20M A round for therapeutic development of tissues generated with microfluidic 3-D bioprinting tech
0
1
8
On BioCentury’s latest #podcast: breaking down the buzz around #LAG3 at #ASCO21, key takeaways from the #BioEquity meeting on What’s Next for Europe & innovation hot spots. with @Laurenmmartz @FishburnSimone @steveusdin1 @jeff_cranmer $BMY $AGEN #COVID19
0
4
9